Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease (Q37864183)

24 August 2017

1 reference

title

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease (English)

1 reference

24 August 2017

3

Alejandro Gugliucci

1 reference

24 August 2017

Kazuhiko Kotani

1

1 reference

PubMed ID

21484479

24 August 2017

Satoshi Kimura

series ordinal

2

1 reference

PubMed ID

21484479

24 August 2017

language of work or name

1 reference

12 April 2011

1 reference

Journal of Physiology and Biochemistry

24 August 2017

1 reference

24 August 2017

67

1 reference

24 August 2017

437-441

1 reference

24 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s13105-011-0092-4

24 August 2017

0 references

cites work

Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Is lipid control necessary in hemodialysis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Studies on human serum paraoxonase/arylesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Effect of hemodialysis on traditional and innovative cardiac markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Ischaemia modified albumin in the diagnosis of acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Cardiovascular problems on hemodialysis: current deficits and potential improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Ischemia-modified albumin predicts mortality in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Screening populations at increased risk of CKD: the Kidney Early Evaluation Program (KEEP) and the public health problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Causes of dysregulation of lipid metabolism in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Oxidant stress in hemodialysis patients: what are the determining factors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0092-4

Atherogenesis in renal patients: a model of vascular disease?

21 January 2018

1 reference

12 December 2020

Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population

1 reference

12 December 2020

Serum paraoxonase activity is decreased in uremic patients

1 reference

12 December 2020

Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis

1 reference

12 December 2020

Serum paraoxonase activities in hemodialyzed uremic patients: cohort study

1 reference

12 December 2020

Serum paraoxonase and arylesterase activities in hemodialysis patients

1 reference

12 December 2020

Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure

1 reference

12 December 2020

Serum Paraoxonase Activity Changes in Uremic and Kidney-Transplanted Patients

1 reference

12 December 2020

Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.

1 reference

12 December 2020

Decrease of serum paraoxonase activity in chronic renal failure.

1 reference

12 December 2020

Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females

1 reference

12 December 2020

The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia

1 reference

12 December 2020

Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients.

1 reference

12 December 2020

PON1 activity is inversely related to LDL apoB carbonyl content in patients with coronary artery disease

1 reference

12 December 2020

Serum paraoxonase activity in uremic predialysis and hemodialysis patients.

1 reference

12 December 2020

10.1007/S13105-011-0092-4

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21484479